Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
148 people get XPH articles and Market Currents by email alert.
Get email alerts on XPH »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
The Best Pharmaceutical InvestmentsCatalyst Investments • Wed, Mar 20 -
-
-
-
-
-
-
Election Could Make Or Break Health Care ETFsTom Lydon • Tue, Sep 18, 2012 -
-
-
-
Pharmaceuticals: Being Lean While The Markets Are MeanEricFinance • Fri, Jul 13, 2012 -
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
The Best Pharmaceutical InvestmentsCatalyst Investments • Wed, Mar 20
-
-
-
-
-
-
-
Election Could Make Or Break Health Care ETFsTom Lydon • Tue, Sep 18, 2012
-
-
-
-
Pharmaceuticals: Being Lean While The Markets Are MeanEricFinance • Fri, Jul 13, 2012
-
-
-
-
-
-
-
There are no Transcripts on XPH.
-
at CNBC.com (Jan 4, 2012)
-
at CNBC.com (Nov 30, 2011)
XPH vs. ETF Alternatives
XPH Description
The SPDR® S&P® Pharmaceuticals ETF seeks to replicate as closely as possible, before expenses, the total return performance of the S&P Pharmaceuticals Select Industry® Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
See more details on sponsor's website
Sector: Healthcare
Country: United States
Key Info
- In Your Portfolio: A Guide to Sector ETFs, A Guide to Healthcare, Pharma and Biotech ETFs
- Asset Class Performance: Themes & Subsectors, Sectors
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
- Tuesday, February 12, 9:00 AM Average cash balances remain at 3.8%, but those overweight cash falls to 2% (from 8%), the lowest read since February 2011, according to the BAML Fund Manager Survey. The favorite sector, though, is a defensive one - Pharmaceuticals (XPH), with those overweight it rising to 27% from 11%. Technology (XLK) saw the biggest drop, a 12 points swing lower in those overweight. Comment!
- Monday, April 30, 2012, 5:20 AM Pure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees. Comment! [Healthcare, Quick Ideas]
- Tuesday, April 17, 2012, 1:29 PM Express Scripts (ESRX +2.5%) says prescription drug spending fell to 2.7% growth in 2011 - the slowest pace in 18 years - due to the introduction of generic medicines that tempered price increases. The company notes that the average co-payment for consumers fell to $12.02 a prescription from $12.10 a year before. Comment! [Healthcare]
- Tuesday, April 3, 2012, 10:04 AM Push comes to shove as pricey life-saving cancer drugs run up against government austerity programs and private payers unwilling to share costs for drugs that run as high as $100K a year. While Big Pharma argues that advanced technology will save money on the development side, companies such as PFE, BMY, RHHBY, and BAYRY.PK run the risk of seeing reduced profits with government-mandated price cuts for their most expensive drugs. 4 Comments [Healthcare, Quick Ideas]
- Wednesday, March 14, 2012, 2:33 PM Downsizing: Only two of the top ten drugmakers increased their promotional spending last year, according to analysis from Cegedim Strategic Data. Overall, global investment on sales and marketing declined 3.4% to $92B. Comment! [Healthcare]
- Wednesday, January 18, 2012, 12:01 PM Research from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil. Comment! [Healthcare, Quick Ideas]
- Friday, January 13, 2012, 1:35 PM Affymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price bid up on potential is over, as investors wait it out to see if firms hash out issues with reimbursements, regulatory hurdles, and safety concerns. "There was a time when products got full value prior to launch. I think we have now swung back in the other direction." Comment! [Healthcare]
- Tuesday, December 27, 2011, 2:54 PM Reuters' John Wasik identifies health care as a sector that will grow in 2012 on the strength of a long-term demographic trend that is pushing up demand for medical services, devices, and pharmaceuticals. He argues that while big pharma ETFs could see a gain, a focus on generic pharmaceutical names looks to be an even better bet as governments and companies look to cut costs. Big pharma ETFs: XPH, IHE, PJP, PPH, DRGS. Generic pharma firms: IPXL, MYL, PRX, TEVA, WPI, PRGO. Comment! [Healthcare, Quick Ideas]
- Tuesday, December 27, 2011, 5:25 AM It could be a very tough year for pharmaceutical firms, which face a slew of patent expiries and new costs from healthcare reforms. Market research firm CreditSights pegs Bristol-Myers (BMY) and Eli Lilly (LLY) as likely to be next year's hardest-hit pharmas, while Abbott (ABT) and J&J (JNJ) will remain relatively sheltered. Comment! [Healthcare]
- Wednesday, December 14, 2011, 7:50 AM Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity. Comment! [Healthcare, Quick Ideas, M&A]
- Tuesday, December 6, 2011, 12:48 PM Sanford Bernstein analyst Tim Anderson's take on Eli Lilly (LLY +3.3%) offers a surprisingly candid view on the roulette-like risks involved in betting on drug company stocks with his estimate that LLY could clear $9B in sales of solanezumab by 2020 or misfire completely with its investment. Anderson on the sector: "Eli Lilly and several of its competitors are willing to spend hundreds of millions of dollars on what is essentially a massive lottery ticket." Comment! [Healthcare, Quick Ideas]
- Monday, November 7, 2011, 9:12 AM Shares of Merck (MRK) nudge up 0.3% premarket after JPMorgan maintains an Overweight rating and a $44 price target along with a ringing endorsement. "While we are not expecting many major surprises on the R&D front... we see a number of interesting late-stage assets in the MRK pipeline and, importantly, continue to view Merck as having one of the strongest core portfolios in pharma." Comment! [Healthcare]
- Friday, September 23, 2011, 1:53 PM Shares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy. 1 Comment [On the Move, Healthcare]
- Wednesday, August 24, 2011, 3:06 PM More on Allergan (AGN +2.4%): Shares started trading higher yesterday in advance of today's announcement the firm's BOTOX solution was approved by the FDA. Comment! [Healthcare, On the Move]
- Wednesday, August 24, 2011, 8:45 AM United Therapeutics (UTHR) falls sharply after disclosing its late-stage drug for pulmonary arterial hypertension failed to improving walking distance for patients. The firm says it will still move forward to seek FDA approval based on an earlier positive study. Shares down 21% premarket. Comment! [On the Move, Healthcare]
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 4/22/2013 (Monday): (1-2) <$XPH $RWR $XOP> SPDR Pharmaceuticals ETF ($XPH)<c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 4/8/2013 (Monday) (1-2-3) SPDR Pharmaceuticals ETF ($XPH) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 3/22/2013 (Friday) (1-2) SPDR Pharmaceuticals ETF ($XPH) SPDR Homebuilders ETF ($XHB) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 3/21/2013 (Thursday) (1-2-3) <$xph $pcy $iwd> spdr Pharmaceuticals ($XPH) <c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
- View all 0 replies
-
Jim Van Meerten
XPH - SPDR S&P Pharma ETF - 88% Barchart technical sell signal - trading below 20, 50 & 100 DMA - Trend Spotter (tm) sell signal - View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 4/22/2013 (Monday): (1-2) <$XPH $RWR $XOP> SPDR Pharmaceuticals ETF ($XPH)<c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 4/8/2013 (Monday) (1-2-3) SPDR Pharmaceuticals ETF ($XPH) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 3/22/2013 (Friday) (1-2) SPDR Pharmaceuticals ETF ($XPH) SPDR Homebuilders ETF ($XHB) <c> - View all 2 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk
-
O. Young Kwon
TANER Rotation Model (TRM) Momentum 3/21/2013 (Thursday) (1-2-3) <$xph $pcy $iwd> spdr Pharmaceuticals ($XPH) <c> - View all 3 replies
-
-
O. Young Kwon: (The numbers are terms in months.) For The TANER System and its four Models, read my article. Link:http://seekingalpha.com/a/hitr yk